Background: Approved topical treatments for seborrheic keratoses (SKs) are an unmet need.
Seborrheic keratoses (SKs) are among the most common benign skin lesions, affecting approximately 83 million Americans. 1 Patients have wide ranges of motivations for treating and/or removing SKs, including embarrassment from the unsightly nature of the lesion, physical irritation or pruritus, and a desire to look younger. 2 Common techniques for SK removal involve cryosurgery, electrosurgery, curettage, or surgical excision. There is, however, a notable lack of well-controlled clinical studies evaluating the efficacy and complication rates of these procedures. Thus, there is a significant and unmet need for a safe, effective, noninvasive, and cosmetically acceptable treatment for this common condition.
Hydrogen peroxide topical solution 40% (w/w) (HP40) (ESKATA [formerly A-101 40%], Aclaris Therapeutics, Inc, Wayne, PA) is a proprietary formulation of a stabilized, high-concentration hydrogen peroxide (HP) solution that is the first and only US Food and Drug Administrationeapproved topical treatment for raised SKs. The results of a dose-ranging, phase 2 study (A-101-SEBK-203) demonstrated that topical HP40 was clinically more efficacious than HP 32.5% for treating facial SKs, with both concentrations significantly better than vehicle. 3 Earlier studies (A-101-SEBK-201/202) showed that HP25% was no more effective than vehicle in treating raised SKs on the trunk or extremities (data on file at Aclaris Therapeutics, Inc). Here, we report results of 2 identical, phase 3, pivotal studies evaluating the safety and efficacy of HP40 compared with the safety and efficacy of vehicle for treatment of 4 target SKs on the face, trunk, and extremities.
METHODS

Study patients
Eligible patients were adults ($18 years of age) with 4 stable, clinically typical, discrete SKs that were more than 0 to 2 mm thick and 5 to 15 mm in length and width. At least 1 SK on the face and at least 1 SK on the trunk or extremities were required. SKs could not be in intertriginous areas or pedunculated, and they could not be covered by hair that would interfere with application of the study drug or the study evaluations. Facial SKs on the eyelids or within 5 mm of the orbital rim were excluded. All patients provided written informed consent before participating.
The study protocol was reviewed and approved by a central institutional review board (Schulman Associates IRB, Blue Ash, Ohio) and was conducted in accordance with ethical principles originating from the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice Guidelines, and local regulatory requirements.
Study design and intervention
The 2 pivotal studies were identically designed, randomized, double-blind, placebo-controlled, phase 3 studies (ClinicalTrials.gov identifiers, NCT02667236 and NCT02667275). Study 1 and study 2 were conducted from February to November 2016 and January to October 2016, respectively; each was conducted at 17 sites in the United States. The physicianinvestigator identified 4 target SKs on each patient during visit 1 (day e13 to 0). Before the start of the study, Global Consulting Partners in Medical Biometrics (New York, NY) randomly assigned medication kits to recruited patients, with access limited to those preparing the kits. At visit 2 (day 1), an investigational center staff member assigned the study medication (HP40 or vehicle) to eligible patients in a 1:1 ratio by selecting patient kits in chronologic sequence and in ascending numeric order (Fig 1) .
Treatments were applied by a nonphysician subinvestigator to maintain blinding because application of HP40 results in transient but visible peroxide whitening effects. On study day 22 (approximately 3 weeks after the first treatment), SKs assessed as not completely clear were re-treated.
The study medication was applied with the use of a self-contained, single-use, disposable applicator, as previously described. 2 The treatment solution was rubbed onto the 4 SKs by using firm pressure in a circular motion for approximately 20 seconds per SK (a total time of 80 seconds for the first round of application to all 4 lesions); the application cycle was then repeated in the same order up to 3 times. This allowed application to be continuous while still meeting protocol requirements to separate applications by approximately 60 seconds. Hydrogen peroxide topical solution, 40% (w/w), is a reasonable noninvasive treatment option for seborrheic keratoses.
were monitored for at least 20 minutes after treatment for adverse events (AEs), including local skin reactions (LSRs).
Efficacy
Efficacy results were reported for each study individually by using the Physician's Lesion Assessment (PLA) scale, which is a proprietary, validated, 4-ordinal number scale (0, clear [no visible SKs]; 1, nearly clear; 2, a thin SK 1 mm or less in depth; and, 3, a thick SK more than 1 mm in depth) developed to quantify the effect treatment of the SK. The PLA scale is the investigator's static assessment of the visibility or thickness of the SK at a single point in time, without access to prior photographs or assessments. Assessments were conducted at screening; at baseline; and on study days 22 (before the second treatment, if required), 50, 78, and 106 (the end of the study).
Efficacy analyses were based on the PLA score on day 106. The primary analysis compared treatment groups on the basis of the proportion of patients for whom all 4 SKs were judged as clear (PLA score of 0) at day 106. The secondary analysis compared treatment groups on the basis of the proportion of patients for whom at least 3 of 4 target lesions were judged as clear (PLA score of 0) at day 106. For both analyses, the Cochran-Mantel-Haenszel test stratified by center was used to calculate the P value.
Exploratory analyses based on per-protocol (PP) populations were performed to assess treatment effect on the basis of the mean per-patient percent of lesions judged as clear (PLA score of 0) and the mean per-patient percent of lesions judged as clear or nearly clear (PLA score #1). The PP population comprised patients who met all the inclusion criteria and none of the exclusion criteria, did not use any prohibited therapies, had all the required study medication treatments, and completed visit 8 (day 106).
Safety
Safety was assessed on the basis of LSRs and AEs by using data pooled from the 2 studies. LSR evaluation was the investigator's assessment of signs and the patient's assessment of symptoms associated with the study medication on each target lesion and the skin immediately surrounding it. Investigator-assessed LSRs included erythema, edema, scaling and/or dryness, vesicles, crusting, erosion, ulceration, postinflammatory hyperpigmentation, postinflammatory hypopigmentation, atrophy, and scarring. Patient-assessed LSR symptoms were stinging and pruritus. LSRs were rated as none (0), mild (1), moderate (2), or severe (3) and were evaluated at baseline and on days 8, 22, 29, 50, 78, and 106. LSRs were summarized by frequency distributions for each symptom, by visit, and by treatment group. AEs were summarized by treatment group and Medical Dictionary for Regulatory Activities (version 19.0) preferred terms.
A sample size of 200 randomized patients per treatment group was based on the results of previous studies. It was assumed that no more than 10% of treated patients would fail to complete the study per protocol; the mean per-lesion rate of completely clear target lesions (a PLA score of 0 at day 106) for the PP population would be 50% or higher for the HP40 group and 5% or lower for the vehicle group; and target lesion responses in each patient were independent. Under these assumptions, the primary efficacy analysis would have 95% or higher power with 2-tailed a value of 0.05.
RESULTS
In all, 450 and 487 patients were enrolled in study 1 (223 in the HP40 group and 227 in the vehicle group) and study 2 (244 in the HP40 group and 243 in the vehicle group), respectively. No patient in study 1 discontinued on account of treatmentrelated AEs, but 2 patients in the HP40 group discontinued as a result of withdrawal of consent, and 1 in each treatment group discontinued on account of nonetreatment-related serious AEs (SAEs). All patients in the HP40 group of study 2 completed the study, whereas 8 patients in the vehicle group discontinued because of withdrawal of consent (n = 5) or loss to follow-up (n = 2) or for another reason (n = 1). No patient discontinued on account of an AE or SAE. In all, 446 (99%) and 479 (98%) patients completed study 1 and study 2, respectively.
The treatment groups were well balanced, with similar demographic and baseline characteristics (Table I) . Patients with Fitzpatrick skin types I through VI were enrolled. However, the majority of patients were white (98%) with Fitzpatrick skin types II (46.7%) and III (30.3%). Both sexes were represented (58% of patients were female), and the mean age was 68.7 years. Most patients (97%) across both studies required 2 treatments. The distribution of treated SKs across both studies was 30%, 59%, and 11% on the face, trunk, and extremities, respectively.
Efficacy
Statistically significantly more patients in the HP40 group than in the vehicle group achieved complete clearance (PLA score of 0) of all 4 SKs (study 1 (Fig 2, A and B) . In exploratory analyses, a higher mean per-patient percentage of lesions treated with HP40 versus with vehicle were deemed clear (PLA score of 0) (study 1, 25% vs 2%; study 2, 34% vs 1%) or clear or nearly clear (PLA score #1) (study 1, 47% vs 10%; study 2, 54% vs 5%) (Fig 2, C and D) . A total of 463 SKs (25.0%) in the HP40 group achieved a PLA score of 1 or lower after the first treatment (evaluated at day 22).
Safety
AEs. In the pooled studies, 100 patients in the HP40 group (21%) reported 145 treatment-emergent AEs (TEAEs) and 88 patients in the vehicle group (19%) reported 126 TEAEs. Most TEAEs were considered mild or moderate in intensity. Three TEAEs in the HP40 group were reported as severe and considered related to study medication: pain at the application site, a postprocedural complication (burning from treatment), and a burning sensation. Ten patients (2%) each in the HP40 and vehicle groups reported 14 and 11 SAEs, respectively; none was considered related to study medication.
LSRs. A total of 1868 and 1880 SKs were evaluated in the HP40 and vehicle groups, respectively. Ten minutes after the initial HP40 treatment, stinging was reported as mild, moderate, or severe for 45% of lesions (844 of 1868), 21% of lesions (397 of 1868), and 5% of lesions (85 of 1868), respectively. Pruritus was reported in 12% (229 of 1868), 5% (91 of 1868), and 1% (19 of 1868) of lesions, respectively, and vesicle formation was reported in 10% (194 of 1868), 0.8% (14 of 1868), and 0.5% (9 of 1868) of lesions, respectively. The results for these LSRs were similar after a second treatment. A few SKs were reported with stinging, pruritus, or vesicles at day 106, with the majority of LSRs graded as mild (Table II) . Hyperpigmentation (5% of lesions), hypopigmentation (2%), scarring (0.2%), and erosions (3%) were observed a week after the initial treatment, with similar results after the second treatment. At day 106, 7.8% of lesions had hyperpigmentation, 3.0% had hypopigmentation, \1% had scarring, and \1% had an erosion (Table II) . Fig 4 shows the percentage of lesions at the baseline and postbaseline visits by severity for the most frequent investigator-assessed LSRs. Erythema and edema were evaluated 10 minutes after the first treatment. Erythema was observed in 91% of lesions (1701 of 1868) and edema was observed in 75% (1409 of 1868). Scaling and crusting were observed 1 week after the initial treatment (in 49% and 45% of lesions, respectively). Similar results for these LSRs were observed after the second treatment. At day 106, the percentages of lesions with each LSR were as follows: erythema 10.1%, edema 0%, scaling 8.0%, and crusting 5.4%. Again, most of these LSRs were mild. Very few SKs in the vehicle group had any LSRs.
DISCUSSION
SKs, particularly in areas of cosmetic concern such as the face, may be aesthetically bothersome as well as medically worrisome to patients and may affect quality of life. 2, 4 An extensive medical literature review revealed no prior large randomized controlled trials evaluating drug or procedural treatment options for removal of SKs. [5] [6] [7] [8] After up to 2 treatments with 40% hydrogen peroxide topical solution, significant improvements were seen in the US Food and Drug Administrationemandated end point of clearing all 4 of 4 SKs from the face, trunk, and extremities compared with vehicle. Adverse effects were limited to local skin reactions, which were mostly mild to moderate and self-limited. differential responses on the basis of lesion location is planned. HP40 provides a novel, standardized, noninvasive, and elegant topical method to treat SKs that affords both patients and practitioners an alternative to the currently used destructive/ablative modalities with narrow therapeutic windows. In the United States, an estimated two-thirds of treated SKs are treated by cryosurgery with liquid nitrogen (data on file at Aclaris Therapeutics, Inc). However, treatment results vary widely; pigmentary changes are common, 9 as are erythema, edema, crusting, and blister and/or bulla formation. 10 Additionally, pain during cryotherapy is significant. The reasons given by patients for avoiding SK treatment include the fear of scarring, permanent hypopigmentation, and treatment-related pain and discomfort. 2 Most LSRs had generally resolved by the end of the study. Scarring, hypopigmentation, and hyperpigmentation occurred only in \1%, 3.0%, and 7.8% of lesions treated with HP40, respectively. Overall, HP40 was extremely well tolerated, with the incidence of TEAEs similar to that with vehicle.
The mechanism of action of HP40 for the treatment of SK has not been fully elucidated. However, HP at various concentrations has been studied across numerous industries. [11] [12] [13] [14] It is considered that with penetration of the proprietary HP40 solution into the SK lesion, HP may act not only through its direct oxidation of organic tissues, generation of reactive oxygen species, and local lipid peroxidation but also through generation of local concentrations of oxygen that are toxic to SK cells. [15] [16] [17] [18] Recent ex vivo skin implant studies of neonatal foreskin suggest that HP40 leads to less cytotoxicity and greater melanocyte viability than with liquid nitrogen. 19 The number of treatment sessions for each lesion in these studies was limited by protocol design to 2, and the optimal number of treatment sessions to clear all lesions was not evaluated. It is likely that even greater efficacy would be achieved if more than 2 HP40 treatment sessions were applied. Other limitations include the relative homogeneity of the study population, the small number of patients with Fitzpatrick skin types V or VI, and the lack of a formal assessment of patient satisfaction with treatment results. Ongoing studies are investigating the safety and efficacy of HP40 in darker skin types as well as the explicit assessment of patient satisfaction with treatment results. Future evaluations of HP40 compared with traditional destructive procedures (eg, cryosurgery) may have clinical utility.
The current results demonstrate that HP40, which is a proprietary, stabilized, high-concentration HPebased topical solution, effectively treats SKs of the face, trunk, and extremities, with a low risk of inducing pigmentary changes and scarring.
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